Carderock Capital Management Inc. Buys 7,344 Shares of STERIS plc $STE

Carderock Capital Management Inc. raised its stake in shares of STERIS plc (NYSE:STE) by 24.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 37,085 shares of the medical equipment provider’s stock after purchasing an additional 7,344 shares during the quarter. STERIS accounts for about 2.3% of Carderock Capital Management Inc.’s investment portfolio, making the stock its 16th biggest position. Carderock Capital Management Inc.’s holdings in STERIS were worth $9,402,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Norges Bank bought a new stake in shares of STERIS during the second quarter valued at approximately $289,132,000. AQR Capital Management LLC lifted its position in STERIS by 178.6% in the third quarter. AQR Capital Management LLC now owns 1,183,070 shares of the medical equipment provider’s stock worth $291,704,000 after purchasing an additional 758,423 shares during the period. Boston Partners acquired a new stake in STERIS during the third quarter worth $158,982,000. Orbis Allan Gray Ltd boosted its stake in STERIS by 36.0% during the second quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock worth $504,486,000 after buying an additional 556,088 shares in the last quarter. Finally, Thrivent Financial for Lutherans increased its holdings in STERIS by 246.4% in the 3rd quarter. Thrivent Financial for Lutherans now owns 553,834 shares of the medical equipment provider’s stock valued at $137,041,000 after buying an additional 393,970 shares during the period. Institutional investors and hedge funds own 94.69% of the company’s stock.

Insider Activity

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of the business’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $237.21, for a total value of $734,876.58. Following the transaction, the director directly owned 705 shares in the company, valued at $167,233.05. The trade was a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.07% of the stock is owned by company insiders.

STERIS Price Performance

Shares of STE stock opened at $220.94 on Tuesday. The stock’s fifty day simple moving average is $246.18 and its 200 day simple moving average is $249.48. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.48 and a quick ratio of 1.75. The firm has a market cap of $21.67 billion, a price-to-earnings ratio of 30.81 and a beta of 1.05. STERIS plc has a one year low of $204.90 and a one year high of $269.44.

STERIS (NYSE:STE) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.The firm’s quarterly revenue was up 9.2% on a year-over-year basis. During the same quarter last year, the company earned $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, analysts expect that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 19th. Investors of record on Tuesday, February 17th were given a dividend of $0.63 per share. The ex-dividend date was Tuesday, February 17th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.1%. STERIS’s dividend payout ratio (DPR) is 35.15%.

Analyst Ratings Changes

STE has been the subject of a number of recent research reports. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research note on Friday, January 9th. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $275.20.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.